Literature DB >> 9199210

Active site architecture of polymorphic forms of human glutathione S-transferase P1-1 accounts for their enantioselectivity and disparate activity in the glutathione conjugation of 7beta,8alpha-dihydroxy-9alpha,10alpha-ox y-7,8,9,10-tetrahydrobenzo(a)pyrene.

X Hu1, R O'Donnell, S K Srivastava, H Xia, P Zimniak, B Nanduri, R J Bleicher, S Awasthi, Y C Awasthi, X Ji, S V Singh.   

Abstract

In this study, we demonstrate that the active site architecture of the human glutathione (GSH) S-transferase Pi (GSTP1-1) accounts for its enantioselectivity in the GSH conjugation of 7beta,8alpha-dihydroxy-9alpha,10alpha-oxy-7,8,9, 10-tetrahydrobenzo(a) pyrene (anti-BPDE), the ultimate carcinogen of benzo(a)pyrene. Furthermore, we report that the two polymorphic forms of human GSTP1-1, differing in their primary structure by a single amino acid in position 104, have disparate activity toward (+)-anti-BPDE, which can also be rationalized in terms of their active site structures. When concentration of (+)-anti-BPDE, which among four BPDE isomers is the most potent carcinogen, was varied and GSH concentration was kept constant at 2 mM (saturating concentration), both forms of hGSTP1-1 [hGSTP1-1(V104) and hGSTP1-1(I104)] obeyed Michaelis-Menten kinetics. The V(max) of GSH conjugation of (+)-anti-BPDE was approximately 3.4-fold higher for hGSTP1-1(V104) than for hGSTP1-1(I104). Adherence to Michaelis-Menten kinetics was also observed for both isoforms when (-)-anti-BPDE, which is a weak carcinogen, was used as the variable substrate. However, (-)-anti-BPDE was a relatively poor substrate for both isoforms as compared with (+)-anti-BPDE. Moreover, there were no significant differences between hGSTP1-1(V104) and hGSTP1-1(I104) in either V(max) or K(m) for (-)-anti-BPDE. The mechanism of differences in kinetic properties and enantioselectivity of hGSTP1-1 variants toward anti-BPDE was investigated by modeling of the two proteins with conjugation product molecules in their active sites. Molecular modeling studies revealed that the differences in catalytic properties of hGSTP1-1 variants as well as the enantioselectivity of hGSTP1-1 in the GSH conjugation of anti-BPDE can be rationalized in terms of the architecture of their active sites. Our results suggest that the population polymorphism of hGSTP1-1 variants with disparate enzyme activities may, at least in part, account for the differential susceptibility of individuals to carcinogens such as anti-BPDE and possibly other similar carcinogens.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9199210     DOI: 10.1006/bbrc.1997.6777

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

1.  Increased skin tumorigenesis in mice lacking pi class glutathione S-transferases.

Authors:  C J Henderson; A G Smith; J Ure; K Brown; E J Bacon; C R Wolf
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

2.  Prostate cancer risk from occupational exposure to polycyclic aromatic hydrocarbons interacting with the GSTP1 Ile105Val polymorphism.

Authors:  Benjamin A Rybicki; Christine Neslund-Dudas; Nora L Nock; Lonni R Schultz; Ludmila Eklund; James Rosbolt; Cathryn H Bock; Kristin G Monaghan
Journal:  Cancer Detect Prev       Date:  2006-10-25

3.  Development of multiplex PCR method for the analysis of glutathione s-transferase polymorphism.

Authors:  Min Sun Kim; Hyoung Jin Kang; Han Jeong Park; Yeon-Joo Yook; Byoung-Don Han; Chul Woo Kim; Nam Hee Kim; Ji Won Lee; Hyery Kim; Kyung Duk Park; Hee Young Shin; Hyo Seop Ahn
Journal:  Mol Diagn Ther       Date:  2011-10-01       Impact factor: 4.074

4.  A high-throughput 1,536-well luminescence assay for glutathione S-transferase activity.

Authors:  Adam Yasgar; John Shultz; Wenhui Zhou; Hui Wang; Fen Huang; Nancy Murphy; Erika L Abel; John DiGiovanni; James Inglese; Anton Simeonov
Journal:  Assay Drug Dev Technol       Date:  2010-04       Impact factor: 1.738

5.  The 341C/T polymorphism in the GSTP1 gene is associated with increased risk of oesophageal cancer.

Authors:  Dongping Li; Collet Dandara; M Iqbal Parker
Journal:  BMC Genet       Date:  2010-06-11       Impact factor: 2.797

6.  Polymorphisms in CYP1B1, GSTM1, GSTT1 and GSTP1, and susceptibility to breast cancer.

Authors:  Beth O Van Emburgh; Jennifer J Hu; Edward A Levine; Libyadda J Mosley; Nancy D Perrier; Rita I Freimanis; Glenn O Allen; Peter Rubin; Gary B Sherrill; Cindy S Shaw; Lisa A Carey; Lynda R Sawyer; Mark Steven Miller
Journal:  Oncol Rep       Date:  2008-05       Impact factor: 3.906

7.  Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer.

Authors:  Jian-Min Yuan; Kenneth K Chan; Gerhard A Coetzee; J Esteban Castelao; Mary A Watson; Douglas A Bell; Renwei Wang; Mimi C Yu
Journal:  Carcinogenesis       Date:  2008-06-09       Impact factor: 4.944

8.  Genetic determinants of emphysema distribution in the national emphysema treatment trial.

Authors:  Dawn L DeMeo; Craig P Hersh; Eric A Hoffman; Augusto A Litonjua; Ross Lazarus; David Sparrow; Joshua O Benditt; Gerard Criner; Barry Make; Fernando J Martinez; Paul D Scanlon; Frank C Sciurba; James P Utz; John J Reilly; Edwin K Silverman
Journal:  Am J Respir Crit Care Med       Date:  2007-03-15       Impact factor: 21.405

9.  Genetic polymorphisms in glutathione S-transferases and cytochrome P450s, tobacco smoking, and risk of non-Hodgkin lymphoma.

Authors:  Briseis A Kilfoy; Tongzhang Zheng; Qing Lan; Xuesong Han; Qin Qin; Nathaniel Rothman; Theodore Holford; Yawei Zhang
Journal:  Am J Hematol       Date:  2009-05       Impact factor: 10.047

10.  Regulation of benzo[a]pyrene-mediated DNA- and glutathione-adduct formation by 2,3,7,8-tetrachlorodibenzo-p-dioxin in human lung cells.

Authors:  Stacy L Gelhaus; Ronald G Harvey; Trevor M Penning; Ian A Blair
Journal:  Chem Res Toxicol       Date:  2010-10-28       Impact factor: 3.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.